Cancer Family
Endocrine Neoplasm
CI-CAN-00000015Explore in graph →
Non-malignant764 active trials16 approved drugs64 evidence items
- NCIt
- C3010
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000015Explore in graph →
Clinical trials
2,725 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01758458 | Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma | terminated | Phase 1 / Phase 2 | 4 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 19, 2017 | clinicaltrials |
| NCT01719861 | Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors | terminated | Phase 2 | 6 | Joel NealOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT00729157 |
| Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy |
| completed |
| Phase 2 |
| 41 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Mar 15, 2017 |
| clinicaltrials |
| NCT00947167 | A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | terminated | Phase 2 | 4 | Pamela L. KunzOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT00050349 | EPO906 in Carcinoid and Other Neuroendocrine Tumors | completed | Phase 2 | 33 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 1, 2017 | clinicaltrials |
| NCT00398320 | Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors | completed | Phase 2 | 40 | Pamela L. KunzOTHER | 1 | Mar 1, 2017 | clinicaltrials |
| NCT00118248 | Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Feb 15, 2017 | clinicaltrials |
| NCT00093782 | Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2017 | clinicaltrials |
| NCT01640847 | MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases | withdrawn | Phase 2 | 0 | ImunonINDUSTRY | 0 | Feb 7, 2017 | clinicaltrials |
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer | terminated | Phase 2 | 2 | Emory UniversityOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT01731925 | A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors(SUNLAND) | unknown | Phase 2 | 44 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 2 | Jan 31, 2017 | clinicaltrials |
| NCT00559949 | Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine | completed | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 2 | Jan 30, 2017 | clinicaltrials |
| NCT00965250 | Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy | completed | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2016 | clinicaltrials |
| NCT01374451 | Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET(COOPERATE-2) | terminated | Phase 2 | 160 | Novartis PharmaceuticalsINDUSTRY | 19 | Dec 20, 2016 | clinicaltrials |
| NCT02661100 | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients | withdrawn | Phase 1 / Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Dec 7, 2016 | clinicaltrials |
| NCT02150213 | Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 | completed | Phase 2 | 59 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 5, 2016 | clinicaltrials |
| NCT02980809 | Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer | unknown | Phase 2 | 60 | First Hospitals affiliated to the China PLA General HospitalOTHER_GOV | 0 | Dec 2, 2016 | clinicaltrials |
| NCT02972320 | Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic | unknown | Phase 2 | 60 | Yunpeng LiuOTHER | 1 | Nov 23, 2016 | clinicaltrials |
| NCT02755675 | uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung | unknown | Phase 2 | 120 | Rigshospitalet, DenmarkOTHER | 1 | Nov 21, 2016 | clinicaltrials |
| NCT02943798 | Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma | unknown | Phase 2 | 118 | Shanghai Chest HospitalOTHER | 0 | Oct 25, 2016 | clinicaltrials |
| NCT02906384 | Memory and MRI Changes With Hippocampus Avoidance Prophylactic Cranial Irradiation(HA-PCI) for Small Cell Lung Cancer(SCLC) | unknown | Phase 2 | 154 | Zhejiang Cancer HospitalOTHER | 1 | Oct 10, 2016 | clinicaltrials |
| NCT02078843 | Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors(GaIN) | terminated | Phase 1 / Phase 2 | 54 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Sep 7, 2016 | clinicaltrials |
| NCT01221675 | TF2- Small Cell Lung Cancer Radio Immunotherapy | completed | Phase 1 / Phase 2 | 18 | Centre René GauducheauOTHER | 1 | Aug 31, 2016 | clinicaltrials |
| NCT01620138 | Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas | completed | Phase 2 / Phase 3 | 21 | Universidade Federal do Rio de JaneiroOTHER | 1 | Aug 22, 2016 | clinicaltrials |
| NCT01045421 | Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies | completed | Phase 1 / Phase 2 | 273 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 15, 2016 | clinicaltrials |
| NCT00869050 | Capecitabine and Temozolomide for Neuroendocrine Cancers | completed | Phase 2 | 41 | Columbia UniversityOTHER | 1 | Jul 25, 2016 | clinicaltrials |
| NCT00682981 | A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC) | completed | Phase 1 / Phase 2 | 218 | Gemin XINDUSTRY | 10 | Jul 21, 2016 | clinicaltrials |
| NCT00458952 | Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma | completed | Phase 1 / Phase 2 | 24 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 13, 2016 | clinicaltrials |
| NCT02152059 | A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy | withdrawn | Phase 2 | 0 | AHS Cancer Control AlbertaOTHER | 1 | Jul 6, 2016 | clinicaltrials |
| NCT01048086 | 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET) | withdrawn | Phase 2 | 0 | University of IowaOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT00416767 | Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery | completed | Phase 2 | 20 | Federation Francophone de Cancerologie DigestiveOTHER | 0 | May 30, 2016 | clinicaltrials |
| NCT01745445 | Clinical Randomized Study of Concurrent Chemo-radiotherapy vs Radiotherapy Alone to Local-advanced Small Cell Lung Cancer (SCLC)(SCLC) | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 17, 2016 | clinicaltrials |
| NCT02772107 | Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer | unknown | Phase 2 / Phase 3 | 132 | Chinese PLA General HospitalOTHER | 1 | May 17, 2016 | clinicaltrials |
| NCT02351505 | Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer | terminated | Phase 2 | 1 | Erin BertinoOTHER | 1 | May 16, 2016 | clinicaltrials |
| NCT01076504 | A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 81 | SCRI Development Innovations, LLCOTHER | 1 | May 5, 2016 | clinicaltrials |
| NCT01658436 | BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. | completed | Phase 2 | 31 | Novartis PharmaceuticalsINDUSTRY | 9 | May 2, 2016 | clinicaltrials |
| NCT01625520 | SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer | completed | Phase 2 | 19 | Federico II UniversityOTHER | 1 | Apr 25, 2016 | clinicaltrials |
| NCT01331525 | The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer(ICE) | completed | Phase 2 | 42 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Apr 14, 2016 | clinicaltrials |
| NCT02738723 | SBRT Compared With IMRT Concurrently With Chemotherapy in Treating Patients With LS-SCLC | unknown | Phase 2 | 50 | Third Military Medical UniversityOTHER | 1 | Apr 14, 2016 | clinicaltrials |
| NCT01628913 | Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors | terminated | Phase 2 | 62 | Novartis PharmaceuticalsINDUSTRY | 8 | Apr 7, 2016 | clinicaltrials |
| NCT01977235 | Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer(TDICC) | unknown | Phase 2 | 110 | Third Military Medical UniversityOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT01396382 | 68Ga-DOTATATE PET Scan in Neuroendocrine Cancer(68Ga) | completed | Phase 2 | 97 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Mar 29, 2016 | clinicaltrials |
| NCT00930891 | Bevacizumab in Extensive Small Cell Lung Cancer(CPC) | completed | Phase 2 / Phase 3 | 143 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 10, 2016 | clinicaltrials |
| NCT00643396 | Phase II Trial of Consolidative Thoracic Radiotherapy for Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 30 | AHS Cancer Control AlbertaOTHER | 1 | Feb 26, 2016 | clinicaltrials |
| NCT00126828 | Study of Radiation Dose Intensity Concurrent With Chemotherapy For Limited Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 18 | AHS Cancer Control AlbertaOTHER | 1 | Feb 24, 2016 | clinicaltrials |
| NCT02688673 | DC Vaccine Combined With CIK Cells in Patients With SCLC | unknown | Phase 1 / Phase 2 | 30 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 0 | Feb 23, 2016 | clinicaltrials |
| NCT00907569 | Hypofractionated Radiotherapy for Limited Stage Small Cell Lung Cancer | completed | Phase 2 | 2 | AHS Cancer Control AlbertaOTHER | 1 | Feb 22, 2016 | clinicaltrials |
| NCT01784107 | A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 45 | Gachon University Gil Medical CenterOTHER | 1 | Feb 10, 2016 | clinicaltrials |
| NCT01121939 | Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers | completed | Phase 2 | 43 | SCRI Development Innovations, LLCOTHER | 1 | Feb 5, 2016 | clinicaltrials |
| NCT01900951 | Temozolomide as Maintenance Therapy in Small Cell Lung Cancer | unknown | Phase 2 | 60 | Chinese PLA General HospitalOTHER | 1 | Jan 26, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Apr 19, 2017source: clinicaltrials